Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status
- 118 Downloads
Patients with metastatic nonseminomatous germ cell tumors (mNSGCT) and a high tumor burden or a poor performance status at initial diagnosis are at risk from potentially life-threatening early complications during or after the first chemotherapy cycle. The outcomes with dose-reduced first cycle of chemotherapy in this population of patients are not well established.
We performed a retrospective analysis of patients with mNSGCT and International Germ Cell Cancer Collaborative Group (IGCCCG) poor risk features. All patients received cisplatin and etoposide-based combinations as first-line treatment. Ultra high tumor marker levels were defined as α-fetoprotein ≥ 100,000 ng/ml or human chorionic gonadotropin ≥ 200,000 mIU/ml. Before 2005, the first treatment cycle was administered at a full dose in our center. After 2005, we used an abbreviated course of cisplatin and etoposide (EP) for the first cycle, followed by subsequent full-dose administration.
From 1987 to 2012, 265 patients with poor risk features according to IGCCCG received first-line chemotherapy. Among them, 63 out of 265 (24%) patients had ultra high tumor marker levels and/or ECOG performance status of 3–4. Dose reduction of the first chemotherapy cycle was associated with a significant decrease of life-threatening complications from 76 to 44% (p = 0.01), but not with the overall survival (HR 0.99, 95% CI 0.44–2.26).
Dose reduction of the first EP cycle by 40–60% in the subgroup of poor risk patients with ultra high tumor marker levels and/or ECOG performance status 3–4 is associated with significantly lowered acute complication rates but not with overall survival.
KeywordsNonseminomatous germ cell tumor Testicular cancers Choriocarcinoma, non-gestational Induction chemotherapy Ultra-high tumor markers Poor risk Extensive tumor burden
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
For this type of study formal consent is not required.
- Logothetis CJ (1984) Choriocarcinoma syndrome. Cancer Bull 36:118–120Google Scholar
- Massard C, Plantade A, Gross-Goupil M et al (2010) Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol 21(8):1585–1588CrossRefPubMedGoogle Scholar
- Tryakin A, Tjulandin S, Titov D et al (2004) C-BOP-3BEP as induction chemotherapy (CT) in nonseminomatous germ cell tumor (NSGCT) patients with poor prognosis. J Clin Oncol ASCO Ann Meeting Proc 22(14S):486 (abstr.) Google Scholar
- Tryakin A, Fedyanin M, Sergeev U et al (2015) Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Efficacy results of phase II trial. J Clin Oncol 33:e15566 (suppl; abstr) Google Scholar